Compare WLDS & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDS | XCUR |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 9.2M |
| IPO Year | 2021 | 2017 |
| Metric | WLDS | XCUR |
|---|---|---|
| Price | $1.39 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 201.0K | 19.3K |
| Earning Date | 08-24-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $44.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $0.94 |
| 52 Week High | $6.50 | $9.48 |
| Indicator | WLDS | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 47.15 |
| Support Level | $1.30 | $0.99 |
| Resistance Level | $1.51 | $1.48 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 69.44 | 49.18 |
Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.